Nirmatrelvir-ritonavir was developed for the treatment of COVID-19 and has shown efficacy
in a Phase 2/3 study of high risk patients (EPIC-HR1). Monitoring for the emergence of viral …

Importance Some patients treated with nirmatrelvir-ritonavir have experienced rebound of
COVID-19 infections and symptoms; however, data are scarce on whether viral rebound …

Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19 | New England Journal of Medicine
Skip to main content The New England Journal of Medicine homepage Advanced Search …

Importance With the widespread use of anti–SARS-CoV-2 drugs, accumulating data have
revealed potential viral load rebound after treatment. Objective To compare COVID-19 …

The clinical characteristics of the rebound phenomenon after antiviral therapy in patients
with Coronavirus disease-2019 (COVID-19) are largely unknown. There are few data …

Background The uptake of nirmatrelvir plus ritonavir (NPR) in patients with coronavirus
disease 2019 (COVID-19) has been limited by concerns around the rebound phenomenon …

Reports of symptomatic rebound and/or test re-positivity among COVID-19 patients following
the standard five-day treatment course of nirmatrelvir/ritonavir have sparked debates …

Background Viral rebound after nirmatrelvir–ritonavir treatment has implications for the
clinical management and isolation of patients with COVID-19. We evaluated an unselected …

Abstract Background Nirmatrelvir/ritonavir (N/R) reduces severe outcomes from coronavirus
disease 2019 (COVID-19); however, rebound after treatment has been reported. We …

In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for COVID-19, 2
patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced …